menu
    • menu
    [{"orgOrder":0,"company":"Biosidus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Agalsidase Beta","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biosidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosidus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biosidus \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Biosidus

    Menu

    Biosidus

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biosidus

                            Argentina arrow
                            Iran Expo
                            Not Confirmed

                            Biosidus

                            Argentina arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Agalsidase Beta

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biosidus Shares Promising Phase III Data for Agalsidase Beta in Fabry

                            Details : AGA BETA BS (agalsidase beta) is a biosimilar of fabrazyme, that provides an exogenous source of α-galactosidase A in Fabry disease patients.

                            Product Name : AGA BETA BS

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            April 16, 2025

                            Lead Product(s) : Agalsidase Beta

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth